Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNIK | Q9UKE5 | 3/20 | 0.49 |
| ▸ | PPARG | P37231 | 9/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 3/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | ECE1 | P42892 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL926382 | 0.94 | TNIK (0.53) | TNIKPPARGCDK8CCR2ECE1 | |
| SCHEMBL927456 | 0.92 | TNIK (0.53) | TNIKCDK8CCR2ECE1BRAF | |
| SCHEMBL926596 | 0.91 | ECE1 (0.53) | TNIKPPARGCDK8CCR2ECE1 | |
| SCHEMBL28787470 | 0.91 | TNIK (0.47) | TNIKPPARGCDK8CCR2ECE1 | |
| SCHEMBL926408 | 0.89 | TNIK (0.52) | TNIKPPARGGRIN1GRIN2BCDK8 | |
| SCHEMBL926554 | 0.89 | TNIK (0.44) | TNIKPPARGGRIN1GRIN2BCDK8 | |
| SCHEMBL926131 | 0.88 | TNIK (0.53) | TNIKPPARGCDK8ECE1 | |
| SCHEMBL27808797 | 0.87 | CCR2 (0.44) | TNIKPPARGGRIN1GRIN2BCDK8 | |
| SCHEMBL926220 | 0.87 | TNIK (0.51) | TNIKPPARGCDK8CCR2 | |
| SCHEMBL928668 | 0.86 | ECE1 (0.53) | TNIKCDK8ECE1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2235015-B1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2016-08-24 | — | — | EP | claimed |
| US-8354425-B2 | Azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-01-15 | — | — | US | claimed |
| CN-101977911-A | Azabicyclic carboxamide derivatives, preparation and therapeutic use thereof | SANOFI AVENTIS | 2011-02-16 | — | — | CN | claimed |
| US-20110009364-A1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | claimed |
| EP-2235015-B1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2016-08-24 | — | — | EP | disclosed |
| US-8354425-B2 | Azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-01-15 | — | — | US | disclosed |
| CN-101977911-A | Azabicyclic carboxamide derivatives, preparation and therapeutic use thereof | SANOFI AVENTIS | 2011-02-16 | — | — | CN | disclosed |
| US-20110009364-A1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009364-A1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | ZYX, XDH, ZFX | TNIK 3921/4885PPARG 1450/4885GRIN1 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.